Business
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of dotinurad MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica ma
About this update from Fortress Biotech, Inc.
[{"type":"image","alt":"Fortress Biotech, Inc.","displaySize":"","headline":null,"caption":"Fortress Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":228,"url":"https://media.zenfs.com/en/globenewswire.com/67d8842b1a3f40249dd9679548ed4862"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3_0qSM501xaK8lgQjQGDIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/67d8842b1a3f40249dd9679548ed4862","width":300,"height":228}},"lazy":false},{"type":"text","content":"Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy ","length":130,"tagName":"p"},{"type":"text","content":"Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of dotinurad","length":127,"tagName":"p"},{"type":"text","content":"MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, closed a $205 million Series A financing to support the advancement of global Phase 3 clinical studies evaluating dotinurad for the treatment of gout. The financing round was co-led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors including Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, funds managed by abrdn Inc., KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners and Prebys Ventures Fund.","length":794,"tagName":"p"},{"type":"text","content":"Crystalys brings together a world-class team with a proven record in gout drug development and deep regulatory success with URAT1 inhibitors. Dotinurad is a next-generation URAT1 inhibitor with potential best-in-class safety and efficacy for the treatment of gout and has demonstrated robust efficacy and a well-defined safety profile across multiple clinical studies in Asia, supporting its approval in Japan, China, Philippines, and Thailand.","length":444,"tagName":"p"},{"type":"text","content":"Lindsay A. Rosenwald, M.D., Fortress’ Executive Chairman, President and Chief Executive Officer, said, “We are ver...